FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62518
News▲ Bullish
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 19:05 UTC
LAST UPDATE2026-10-02 19:05 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Expanded FDA label widens Jaypirca's addressable CLL/SLL population, supporting LLY oncology revenue.
Jaypirca label expansion adds untreated CLL patients
CATALYST TO WATCH
Launch uptake and payer coverage decisions
MAIN RISK
Competitive BTK class pressure on pricing
FULL DISPATCH
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare, LLY
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
Finance Watch: Biopharmas Maintain Strong First-Day, Post-IPO Momentum2026-10-02 17:47 UTC
Finance Watch: Biopharmas Maintain Strong First-Day, Post-IPO Momentum2026-10-02 17:47 UTC
←CORRELATIONshares Healthcare
Rice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the body2026-10-02 18:01 UTC
Rice Biotech Launch Pad invents 'living pharmacy' designed to produce therapeutics inside the body2026-10-02 18:01 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.